A phase Ib/IIa study of AG019 for the treatment of early onset type 1 diabetes (T1D).
Phase of Trial: Phase I/II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs AG-019 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors ActoBio Therapeutics
- 05 Apr 2018 New trial record
- 29 Mar 2018 According to an Intrexon Corporation media release, ActoBio Therapeutics (a wholly owned subsidiary of Intrexon Corporation), received an approval from FDA for their IND application to initiate this study.